184 related articles for article (PubMed ID: 32099036)
41. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
[TBL] [Abstract][Full Text] [Related]
42. [Real-time quantitative study of minimal residual disease in childhood B cell acute lymphoblastic leukemia].
Jia YP; Liu GL; Zhang LP
Zhonghua Er Ke Za Zhi; 2004 Aug; 42(8):600-4. PubMed ID: 15347448
[TBL] [Abstract][Full Text] [Related]
43. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia.
Gawad C; Pepin F; Carlton VE; Klinger M; Logan AC; Miklos DB; Faham M; Dahl G; Lacayo N
Blood; 2012 Nov; 120(22):4407-17. PubMed ID: 22932801
[TBL] [Abstract][Full Text] [Related]
44. [Detection of minimal residual diseases in B-cell tumors using PCR specific for the immunoglobulin heavy chain gene].
Matolcsy A; Borbényi Z; Demeter J; Egyed M; Fekete S; Földi J; Gergely L; Kajtár P; Kelényi G; Kiss A; László T; Lehoczky D; Losonczy H; Nagy M; Pál K; Pálóczy K; Radványi G; Semsei I; Varga G; Udvardy M
Orv Hetil; 2000 Jun; 141(25):1403-6. PubMed ID: 10934884
[TBL] [Abstract][Full Text] [Related]
45. Minimal Residual Disease Detection and Evolved
Wu J; Jia S; Wang C; Zhang W; Liu S; Zeng X; Mai H; Yuan X; Du Y; Wang X; Hong X; Li X; Wen F; Xu X; Pan J; Li C; Liu X
Front Immunol; 2016; 7():403. PubMed ID: 27757113
[TBL] [Abstract][Full Text] [Related]
46. Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience.
Dawidowska M; Jółkowska J; Szczepański T; Derwich K; Wachowiak J; Witt M
Arch Immunol Ther Exp (Warsz); 2008; 56(6):409-18. PubMed ID: 19043668
[TBL] [Abstract][Full Text] [Related]
47. Polymerase chain reaction-single-strand conformational polymorphism analysis of antigen receptor rearrangements in monitoring therapeutic effect in childhood ALL.
Thunberg U; Sällström J; Frost BM; Lönnerholm G; Sundström C
Diagn Mol Pathol; 1998 Jun; 7(3):146-51. PubMed ID: 9836069
[TBL] [Abstract][Full Text] [Related]
48. [Characteristics of T cell receptor beta gene rearrangements and its role in minimal residual disease detection in childhood T-cell acute lymphoblastic leukemia].
Liu JY; Li ZG; Gao C; Cui L; Wu MY
Zhonghua Er Ke Za Zhi; 2008 Jul; 46(7):487-92. PubMed ID: 19099802
[TBL] [Abstract][Full Text] [Related]
49. Shared clonal IGH rearrangement in BCP-ALL occurring after CLL: pitfalls and implications for MRD monitoring.
Derrieux C; Gish A; Caulier A; Grardel N; Garidi R; Joris M; Assouan D; Poulain S; Decool G; Ferret Y; Caillault-Venet A; Marolleau JP; Preudhomme C; Boyer T
Br J Haematol; 2020 Nov; 191(3):506-509. PubMed ID: 32754904
[No Abstract] [Full Text] [Related]
50. The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia.
de Haas V; Breunis WB; Dee R; Verhagen OJ; Kroes W; van Wering ER; van Dongen JJ; van den Berg H; van der Schoot CE
Br J Haematol; 2002 Jan; 116(1):87-93. PubMed ID: 11841400
[TBL] [Abstract][Full Text] [Related]
51. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
Bone Marrow Transplant; 2000 Apr; 25(8):843-51. PubMed ID: 10808205
[TBL] [Abstract][Full Text] [Related]
52. Differences in immunoglobulin heavy chain gene rearrangmeent patterns between bone marrow and blood samples in childhood precursor B-acute lymphoblastic leaukemia at diagnosis.
Beishuizen A; Verhoeven MA; Hählen K; van Wering ER; van Dongen JJ
Leukemia; 1993 Jun; 7(6):60-3. PubMed ID: 8315958
[TBL] [Abstract][Full Text] [Related]
53. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.
Logan AC; Gao H; Wang C; Sahaf B; Jones CD; Marshall EL; Buño I; Armstrong R; Fire AZ; Weinberg KI; Mindrinos M; Zehnder JL; Boyd SD; Xiao W; Davis RW; Miklos DB
Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21194-9. PubMed ID: 22160699
[TBL] [Abstract][Full Text] [Related]
54. IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis.
Lovisa F; Mussolin L; Corral L; Pillon M; Cazzaniga G; Biondi A; Rosolen A
Lab Invest; 2009 Oct; 89(10):1182-6. PubMed ID: 19668242
[TBL] [Abstract][Full Text] [Related]
55. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
56. Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: multi-institutional collaborative study in Japan.
Imashuku S; Terui K; Matsuyama T; Asami K; Tsuchiya S; Ishii E; Kawa K; Kosaka Y; Eguchi H; Tsuchida M; Ikuta K; Kato S; Koizumi S; Okamura J; Morimoto A; Hibi S; Hamaoka K;
Bone Marrow Transplant; 2003 Jun; 31(12):1127-35. PubMed ID: 12796792
[TBL] [Abstract][Full Text] [Related]
57. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
58. Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications.
Darzentas F; Szczepanowski M; Kotrová M; Hartmann A; Beder T; Gökbuget N; Schwartz S; Bastian L; Baldus CD; Pál K; Darzentas N; Brüggemann M
Front Immunol; 2023; 14():1125017. PubMed ID: 37143651
[TBL] [Abstract][Full Text] [Related]
59. Rearrangement status of the malignant cell determines type of secondary IgH rearrangement (V-replacement or V to DJ joining) in childhood B precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van den Berg H; van Leeuwen EF; Behrendt H; Slater RR; von dem Borne AE; van der Schoot CE
Leukemia; 1997 Aug; 11(8):1258-65. PubMed ID: 9264379
[TBL] [Abstract][Full Text] [Related]
60. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Kasai M; Kakinoki Y; Masauzi N; Morioka M; Kawamura T; Iwasaki H; Asaka M; Imamura M
Am J Hematol; 2005 Nov; 80(3):181-7. PubMed ID: 16247752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
